Literature DB >> 16360345

Effect of vasopressin on hemodynamics in patients with refractory cardiogenic shock complicating acute myocardial infarction.

Sanjit Jolly1, Gary Newton, Eric Horlick, Peter H Seidelin, Heather J Ross, Mansoor Husain, Vladimir Dzavik.   

Abstract

In a retrospective study of 36 patients who developed cardiogenic shock after myocardial infarction, intravenous vasopressin therapy increased mean arterial pressure from 56 to 73 mm Hg at 1 hour (p < 0.001) and maintained it for 24 hours without changing pulmonary capillary wedge pressure, cardiac index, urine output, or other inotropic requirements. After norepinephrine administration, mean pulmonary capillary wedge pressure increased at 1 hour from 21 to 24 mm Hg (p = 0.04); however, this increase was not sustained at 12 and 24 hours. Norepinephrine was associated with a significant increase in cardiac power index at 24 hours, whereas there was only a trend for an increase in cardiac power with vasopressin therapy. In a cohort of patients who developed refractory cardiogenic shock after myocardial infarction, vasopressin was associated with increased mean arterial pressure and no adverse effect on other hemodynamic parameters.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16360345     DOI: 10.1016/j.amjcard.2005.07.076

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  21 in total

Review 1.  [Cardiogenic shock].

Authors:  S Rasche; C Georgi
Journal:  Anaesthesist       Date:  2012-03       Impact factor: 1.041

Review 2.  Pathophysiology, diagnosis, and treatment of infarction-related cardiogenic shock.

Authors:  M Buerke; H Lemm; S Dietz; K Werdan
Journal:  Herz       Date:  2011-03       Impact factor: 1.443

3.  Vasopressin and ischaemic heart disease: more than coronary vasoconstriction?

Authors:  Pierre Asfar; Peter Radermacher
Journal:  Crit Care       Date:  2009-07-22       Impact factor: 9.097

Review 4.  New approaches to therapy of cancers of the stomach, colon and pancreas based on peptide analogs.

Authors:  A V Schally; K Szepeshazi; A Nagy; A M Comaru-Schally; G Halmos
Journal:  Cell Mol Life Sci       Date:  2004-05       Impact factor: 9.261

5.  [Cardiogenic shock].

Authors:  S Rasche; C Georgi
Journal:  Herz       Date:  2013-03       Impact factor: 1.443

Review 6.  Management of cardiogenic shock complicating myocardial infarction.

Authors:  Alexandre Mebazaa; Alain Combes; Sean van Diepen; Alexa Hollinger; Jaon N Katz; Giovanni Landoni; Ludhmila Abrahao Hajjar; Johan Lassus; Guillaume Lebreton; Gilles Montalescot; Jin Joo Park; Susanna Price; Alessandro Sionis; Demetris Yannopolos; Veli-Pekka Harjola; Bruno Levy; Holger Thiele
Journal:  Intensive Care Med       Date:  2018-05-16       Impact factor: 17.440

7.  Vasopressor stays vasopressor and inotrope stays inotrope!

Authors:  Günter Luckner; Walter R Hasibeder; Martin W Dünser
Journal:  Crit Care       Date:  2008-04-14       Impact factor: 9.097

8.  [Vasopressin as a rescue vasopressor agent. Treatment of selected cardiogenic shock states].

Authors:  V D Mayr; G Luckner; S Jochberger; V Wenzel; W R Hasibeder; M W Dünser
Journal:  Anaesthesist       Date:  2007-10       Impact factor: 1.041

Review 9.  [New pharmacological treatment approaches to cardiogenic shock].

Authors:  M Buerke; M Russ; K Werdan
Journal:  Internist (Berl)       Date:  2007-12       Impact factor: 0.743

10.  Low-dose vasopressin infusion results in increased mortality and cardiac dysfunction following ischemia-reperfusion injury in mice.

Authors:  Toonchai Indrambarya; John H Boyd; Yingjin Wang; Melissa McConechy; Keith R Walley
Journal:  Crit Care       Date:  2009-06-23       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.